At the higher doses, results were very consistent: All participants lost at least 5% of their body weight Around 3 in 4 lost 15% or more With placebo, only around 1 in 4 lost 5% or more Phase 3 update (TRIUMPH-4, 68 weeks, topline results) In December 2025 , Eli Lilly shared early (topline) results from a larger phase 3 study (TRIUMPH-4)
Her arm became less swollen and softer, getting "significantly better after the weight loss, Dayan says
GLP-1 Telehealth Access by State GLP-1 Telehealth Access by State an evidence-based article in the RenewMD Learn library
Its crucial to investigate whether GLP-1 receptor agonists and SGLT-2 inhibitors could serve as disease-modifying therapies for Alzheimers disease in humans by targeting the diseases biology directly, beyond these drugs known antidiabetic effects, Dr
However, suitability depends on individual metabolic profile, baseline health status, and how genetic factors related to GLP-1 signaling pathways may influence treatment response and tolerability